Western medicine often functions more like a high-tech patient-processing machine than a high-touch people-healing mission. This can and must change, argue three distinguished healthcare thought leaders.
The FDA has identified another safety concern with Johnson & Johnson MedTech's Automated Impella Controllers. This comes after the devices were linked to five separate recalls in 2025.
The Alliance for Aging Research wants CMS to go through with policy changes that could make many more patients eligible for TAVR. The agency is currently considering the changes, and a final decision is expected in June.
"Pulmonary embolism is fundamentally a cardiovascular disease, where restoration of hemodynamic stability, beyond simple clot removal, is the key determinant of patient recovery,” one researcher explained.
First revealed in March, the incident was confirmed to be months long. NYC Health + Hospitals blamed the intrusion on an unnamed third-party vendor. Stolen data includes medical records, finger and palm prints, and location data from patients and workers alike.
HHS Secretary Robert F. Kennedy Jr. is tapping Stephanie Haridopolos, MD, to temporarily fill the role and carry out some of the duties handled by the “nation’s doctor.”
Sanofi's Merilog is a new biosimilar substitute for Novo Nordisk’s NovoLog. It can be used to treat adult and pediatric patients with type 1 and type 2 diabetes.
Women covered by Medicaid are about 38% likelier to undergo uterine artery embolization, according to new research from the Neiman Health Policy Institute.
Western medicine often functions more like a high-tech patient-processing machine than a high-touch people-healing mission. This can and must change, argue three distinguished healthcare thought leaders.
The FDA has identified another safety concern with Johnson & Johnson MedTech's Automated Impella Controllers. This comes after the devices were linked to five separate recalls in 2025.
The Alliance for Aging Research wants CMS to go through with policy changes that could make many more patients eligible for TAVR. The agency is currently considering the changes, and a final decision is expected in June.
